CAGE Bio earns recognition as the Rising Star by the BioNorthTX at the iC3® Summit 20
Transforming ionic liquids into healthcare solutions
Transforming ionic liquids into healthcare solutions
CAGE Bio Inc., currently a resident company at Johnson & Johnson Innovation, JLABS @ MBC BioLabs, is a clinical-stage startup exploiting its proprietary deep eutectic ionic liquid platform to develop novel products for dermatology, inflammation, and immunology.
We believe that systemic exposure to drugs should be an exception. Our mission is to develop highly
effective products for localized treatment thereby minimizing side effects from systemic exposure.
Deep eutectic ionic liquids exhibit broad-spectrum antimicrobial action in addition to exceptional solvation and permeation enhancement. Deep eutectic ionic liquids have shown the ability to deliver proteins (eg insulin) and charged macromolecules (eg siRNA) across the stratum corneum.
20+ years in drug development through approvals in the US and EU. Held senior positions at Elan, Alkermes, ALZA (J&J). Co-Founder, Incline Therapeutics acquired by The Medicines Company.
Professor, Bioengineering and Biologically Inspired Engineering, Harvard University.
Member of the U.S. National Academy of Engineering, National Institute of Medicine, National Academy of Inventors.
Serial biotech entrepreneur, multiple startups and exits. StrataGent(acquired by Corium), StemPar, OncoNano(raised $100M), Symyx, ForSightV5 (acquired by Allergan for $90M).